Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs SOLAI Limited — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 14.3× SOLAI Limited's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and SOLAI Limited for 40 Days on average.
| HALO | SLAI | |
|---|---|---|
Market Cap | $12.58B | $880.09M |
Volume | 2,179,278 | 122,720 |
Sector | Health | Technology |
52-Week High | $115.22 | $21.63 |
52-Week Low | $61.63 | $2.74 |
Typical Hold Time | 1 Days | 40 Days |
Enterprise Value | $14.49B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLAI trades at $3.72 with no recent price movement. The stock shows a bullish technical signal despite concerning fundamentals, including negative profit margins (-134.76% net income margin) and declining revenue from $57M in 2022 to $23M in 2025. The company received a delisting notice from NYSE in July 2026, creating significant uncertainty. Cash flow remains negative at -$1.47M, though the P/B ratio of 0.35 suggests potential undervaluation based on book value.
Outlook remains highly speculative given delisting proceedings and persistent losses. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment. Investment opportunity exists only for risk-tolerant investors betting on turnaround potential, while major risks include delisting execution, continued cash burn, and competitive pressures in the AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
